Comparison of EpCAM-ReTARGpp65 with the EpCAM-directed BiTE solitomab indicated a similar cancer cell elimination capacity but at ~55% decreased levels of T cell-secreted proinflammatory cytokines. The gene discussed is EPCAM; the disease is cancer.